Sandoz Canada has confirmed that it has launched its Hyrimoz (adalimumab) biosimilar rival to Humira, after it and other Canadian biosimilars players set their sights on a mid-February launch.
Last year, Sandoz had suggested that it would launch Hyrimoz around 15 February, while Fresenius Kabi had also pointed to...






